This Article Free Full Text Free Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Helmus, M. N. Articles by Cebon, D. Search for Related Content PubMed PubMed Citation Articles by Helmus, M. N. Articles by Cebon, D. Social Bookmarking                         What's this?

Biocompatibility: Meeting a Key Functional Requirement of Next-Generation Medical Devices

¹ Medical Devices, Biomaterials, Drug Delivery, and Nanotechnology, Worcester, Massachusetts, USA
² 3M Corporation, North Oaks, Minnesota, USA
³ Granta Design Limited, Cambridge, United Kingdom

Correspondence: Address correspondence to: Michael N. Helmus, PhD, Consultant: Medical Devices, Biomaterials, Drug Delivery, and Nanotechnology, 2 Jamesbury Dr., Worcester, MA 01609; e-mail: Mhelmus571{at}aol.com.

The array of polymeric, biologic, metallic, and ceramic biomaterials will be reviewed with respect to their biocompatibility, which has traditionally been viewed as a requirement to develop a safe medical device. With the emergence of combination products, a paradigm shift is occurring that now requires biocompatibility to be designed into the device. In fact, next-generation medical devices will require enhanced biocompatibility by using, for example, pharmacological agents, bioactive coatings, nanotextures, or hybrid systems containing cells that control biologic interactions to have desirable biologic outcomes. The concept of biocompatibility is moving from a "do no harm" mission (i.e., nontoxic, nonantigenic, nonmutagenic, etc.) to one of doing "good," that is, encouraging positive healing responses. These new devices will promote the formation of normal healthy tissue as well as the integration of the device into adjacent tissue. In some contexts, biocompatibility can become a disruptive technology that can change therapeutic paradigms (e.g., drug-coated stents). New database tools to access biocompatibility data of the materials of construction in existing medical devices will facilitate the use of existing and new biomaterials for new medical device designs.

Key Words: Biomaterial • biocompatibility • bioactive • biostable • biodegradable • drug eluting • implant • database

Abbreviations: Co-Cr-Mo, cobalt-chrome-molybdenum • ISO, International Standards Organization • OCP, FDA’s Office of Combination Products • PMMA, polymethylmethacrylate • PTFE, poly(tetrafluoroethylene) • PVC, poly(vinyl chloride) • SIBS, styrene-isobutylene-styrene triblock copolymer or Poly(Styrene-b-isobutylene-b-styrene) • ULTI, ultra low temperature isotropic carbon

Toxicologic Pathology, Vol. 36, No. 1, 70-80 (2008)
DOI: 10.1177/0192623307310949


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?